by ecancer reporter Janet Fricker
In a study based on the genetic finger print of tumours taken from 2000 breast cancers patients, researchers from the UK and Canada have reclassified breast cancer into 10 distinct categories of disease.
The landmark Cancer Research UK study, published online today in Nature, has been heralded as having the potential to create a new treatment paradigm that should allow doctors to eventually better tailor treatments to individual breast cancers patients.
In the international study researchers, led by Carlos Caldas (University of Cambridge) and Samuel Aparicio (University of British Columbia, Vancouver), first studied the DNA of the tumours.
Focusing on copy number variations (these affect large stretches of DNA) and single nucleotide polymorphisms (SNPs; these affect single bases), they compared tumour DNA with matched healthy tissue DNA to pinpoint the cancer-specific changes and compile ‘genetic maps’ for each tumour. Next, they analysed RNA to show whether genes were ‘on’ or ‘off’.
Combining all their data gave them a ‘high-resolution genetic profile ‘for each individual tumour on a remarkable scale.
The study was first undertaken in a sample of 1000 tumours, and then reproduced in a second sample of 1000 tumours. Since this retrospective study was undertaken on archived material, it enabled the investigators to know the treatment outcomes for patients at the time of the investigation.
The main results from the study showed:
“Our results will pave the way for doctors in the future to diagnose the type of breast cancer a woman has, the types of drugs that will work, and those that won’t, in a much more precise way than is currently possible,” said Carlos Caldas. “This research won’t affect women diagnosed with breast cancer today. But in the future, breast cancer patients will receive treatment targeted to the genetic fingerprint of their tumour.”
Samuel Aparicio, co-lead author of the study, added, “The size of this study is unprecedented and provides insights into the disease such as the role of immune response, which will stimulate other avenues of research.”
Reference
C Curtis, S Shahm S Chin, et al. The genomic and transciptomatic architecture of 2,000 breast tumours reveals novel subgroups. Nature. doi:10.1038/nature10983
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.